Compare SIFY & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIFY | FTH |
|---|---|---|
| Founded | 1995 | 1999 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 881.9M | 835.7M |
| IPO Year | 1999 | 2021 |
| Metric | SIFY | FTH |
|---|---|---|
| Price | $12.59 | $19.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $55.38 |
| AVG Volume (30 Days) | 27.7K | ★ 336.9K |
| Earning Date | 10-28-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $66.06 | N/A |
| Revenue Next Year | $18.27 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.09 | $16.57 |
| 52 Week High | $17.85 | $42.14 |
| Indicator | SIFY | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 50.30 | 38.29 |
| Support Level | $12.10 | N/A |
| Resistance Level | $14.38 | $21.97 |
| Average True Range (ATR) | 0.48 | 2.21 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 75.87 | 32.37 |
Sify Technologies Ltd is the integrated information and communication technology (ICT) solutions and services companies in India, offering end-to-end solutions with a comprehensive Product offering delivered over a common network infrastructure. It is providing services to enterprise customers, comprising Network services, Data Center services, and Digital Services which represent its operating segments. Majority of revenue comes from Network services segment which focuses India Network Business, World'wide Network Business, Wholesale Voice, Retail Voice. Network services offers Secure Connect, Express Connect, Partner Connect, Data Center/Cloud Interconnect portfolio services. It has presence in India, and Rest of world. It generates maximum revenue from India.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.